The GvHD Hub are proud to present expert interviews directly from the 61st American Society of Hematology (ASH) meeting in Orlando, US. This interview with Ali Bazarbachi, American University of Beirut, Beirut, LB, was on the topic of novel prophylactic therapies available before and after transplantation to reduce the risk of graft- versus-host disease.
Ali Bazarbachi discusses the evolving treatment landscape of GvHD prophylaxis and treatment. He explains the success of post-transplant cyclophosphamide in the haploidentical setting. He also discusses the results of a study that examined the use of post-transplant cyclophosphamide in the match related/unrelated setting. Ali Bazarbachi concludes by summarizing the results of a study from the Acute Leukaemia Working Party (ALWP) EBMT, that examined the efficacy of anti-thymocyte globulin or post cyclophosphamide to reduce chronic GvHD.